Finance

Sun Pharma is set to acquire Organon in a $11.75 billion deal, while IMG Pharma enters a definitive agreement to purchase Matsumoto, signaling continued global consolidation and portfolio expansion across the pharmaceutical industry.

UnitedHealth Group reported stronger-than-expected first-quarter earnings and raised its full-year outlook, signaling improving cost control and early progress in stabilizing performance.

Samsung Bioepis’ SVP and head of US commercial discusses the pricing, regulatory, and broader issues impacting the biosimilars market.

Biotech financing activity this week underscores strong investor backing for platform-driven innovation, with capital flowing into ADC development, precision immunology, multi-cancer diagnostics, and non-invasive oncology technologies aimed at addressing persistent gaps in care.

Our April issue's feature profile offers a reminder that, increasingly, the CFO role in pharma is not just about stewardship but about shaping direction.

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

The U.S. government’s contract with Shionogi highlights renewed public-private investment in antimicrobial resistance and biodefense, aiming to strengthen domestic manufacturing and expand the role of novel antibiotics against high-priority threats.

Shah Capital escalates its pressure campaign against Novavax leadership, requesting changes and strategic overhauls amid ongoing performance concerns.

Merck is acquiring Terns Pharmaceuticals for $6.7 billion to bolster its oncology pipeline, while Shionogi is set to purchase 50% of Apnimed's ownership of SASS.

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its remaining stake at a loss, Quotient Therapeutics enters a multi-year research collaboration with Merck to discover novel drug targets in inflammatory bowel disease, and Gilead Sciences agrees to acquire privately held Ouro Medicines in a deal valued at up to $2.18 billion.

Inclusive Capital Partners sold a stake worth about 0.9 % of the company.

Pfizer urges shareholders to reject an unsolicited mini-tender offer from Tutanota LLC, who is seeking to purchase up to 1 million Pfizer shares at $32.00-per-share.

The funding rounds are part of a broader effort to advance next-generation T-cell engager platforms targeting cancers.

Fresh off 2025, where the sectors delivered strong stock gains and selective financing momentum despite volatile markets, companies navigate policy headwinds, patent cliffs, and shifting global innovation dynamics, factors that favor strategically driven growth pursuits ahead.

Cognito Therapeutics and NexCure have each closed new funding rounds this week, advancing an at-home Alzheimer's stimulation device and a platform to bring CAR-T therapy to community settings

Teva Pharmaceuticals has secured $400 million from Blackstone Life Sciences to advance duvakitug, an experimental monoclonal antibody in Phase III trials for ulcerative colitis and Crohn's disease.

Novo Nordisk is investing to expand its Athlone, Ireland facility, aiming to boost global manufacturing capacity for oral GLP-1 treatments.

Greater Miami is rapidly emerging as an international biotech hot spot—as capital, talent, and infrastructure converge to transform the region from a tourism-driven economy into a globally connected life sciences innovation hub.

Three key takeaways from the JPM industry reset offer clear clues to how biopharma companies—and leaders—must adapt to stand out and ultimately thrive in 2026.

Special Guest Op-Ed: What a decade of collaboration and shared effort reveals about the future of drug development.

QuantX Biosciences and Pandorum Technologies have closed new Series B financing rounds, raising $85 million and $18 million respectively, to advance their platform-driven approaches.

The EY deals leader discusses recent findings and trends from 2025.

Novo Nordisk posted strong 2025 sales growth driven by obesity treatments and U.S. market performance, but tempered operating profits signal a more cautious outlook for 2026.

Novartis reported solid full-year growth and margin expansion in 2025, but also set the stage for a challenging year ahead marked by major patent expirations.

The facility builds on Eli Lilly's $50 Billion investment strategy to strengthen the company's domestic manufacturing capabilities.